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Introduction {#sec1}
============

Differentiation of functional hematopoietic stem and progenitor cells (HS/PCs) from human pluripotent stem cells (hPSCs) provides a unique source of therapeutic cells for blood diseases and thus generates wide research interests in the field ([@bib11], [@bib29], [@bib37]). Indeed, significant progress have been made on how to drive hPSC differentiation toward different blood lineages ([@bib13], [@bib22], [@bib43], [@bib46], [@bib49]). However, HS/PCs derived from hPSCs through current differentiation protocols showed very limited engraftment and hematopoietic reconstitution in vivo ([@bib13], [@bib45], [@bib49]). These findings indicate that the in vitro conditions for driving blood differentiation do not fully recapitulate the mechanisms of hematopoiesis in vivo. During development, numerous studies using different models such as zebrafish and mouse embryos have shown that hematopoietic stem cells (HSCs) emerge directly from a unique endothelial population, the hemogenic endothelial cells (HECs), through a special process called endothelial to hematopoietic transition (EHT) ([@bib2], [@bib3], [@bib38]). During EHT, cells with endothelium phenotype gradually acquire hematopoietic morphology and characteristics. The EHT process has also been detected during the in vitro blood differentiation of human PSCs ([@bib14], [@bib33]). Therefore, systematic analysis and comparison of the EHT process in vivo and in vitro at the molecular level might aid the generation of functional HS/PCs from hPSCs.

To date, a number of key transcription factors (TFs) and signaling pathways that control EHT have been identified in mouse and zebrafish ([@bib7], [@bib10], [@bib23], [@bib47], [@bib48]). For instance, in mouse embryo, *Runx1* is highly expressed in both HECs and HSCs and plays essential roles in EHT ([@bib8]). GATA2 is another factor that is known to be critical for hematopoiesis ([@bib35], [@bib42]). Mouse embryo lacking Gata2 died at an early stage due to the severe anemia ([@bib16], [@bib27], [@bib28], [@bib39]). Notably, mouse HECs without Gata2 failed to produce long-term repopulating HSCs due to an impaired EHT ([@bib12]). We have also demonstrated that human embryonic stem cells (hESCs) with *GATA2* deficiency exhibited a reduced EHT during blood differentiation ([@bib18]). These reports suggest that the critical role of GATA2 in regulating EHT is conserved in different species and systems. In addition to the EHT process, TFs also play essential roles in determining the normal function of HS/PCs. For example, overexpression of *Hoxb4* could enhance the engraftment of hematopoietic progenitor cells (HPCs) derived from mouse ESCs ([@bib24]). However, HOXB4 did not show a similar function in hESC-derived HPCs ([@bib45]), indicating that different TFs need be identified for human cells. Indeed, many other factors such as HOXA9 ERG, RORA, SOX4, and MYB have been tested for promoting engraftment of HS/PCs generated in vitro. However, none of these factors were able to mediate long-term engraftment of these in vitro generated human HS/PCs ([@bib13], [@bib34], [@bib41]). Another approach to generate HS/PCs in vitro is through direct specification of functional HECs into HS/PCs. Indeed, it has been shown that endothelial cells isolated from the aorta gonad mesonephros (AGM) region at embryonic day 10.5 (E10.5) to E11.5 mouse embryos efficiently generated HPCs in vitro ([@bib26]). However, how to precisely discriminate the functional HECs from non-hemogenic ECs remains challenging. The inaccessibility of HECs largely hampers the further understanding of their molecular determinants during hematopoiesis.

To further investigate the molecular program involved in HEC determination during human hematopoiesis, we generated a *GATA2*/*eGFP* reporter in H1 hESCs through gene targeting, referred as *GATA2*^*w*/*eGFP*^ hESCs. Based on an hPSC blood differentiation protocol in co-culturing with OP9 ([@bib43]), we show that GATA2/eGFP expression almost exclusively marks the functional HECs with the potential to produce CD34^+^CD43^+^ HPCs. We then separated HECs from non-hemogenic ECs in hESC differentiation by cell sorting based on GATA2/eGFP expression. Through further comparative analysis of whole-transcriptome data on GATA2/eGFP^+^ HECs and GATA2/eGFP^−^ non-hemogenic ECs, we constructed a regulatory network positive or negative for hemogenic endothelial (HE) determination. Moreover, we identified a list of differentially expressed cell-surface markers between GATA2/eGFP^+^ HECs and GATA2/eGFP^−^ ECs. Among them, CD61 precisely labeled functional HECs not only in hESC differentiation but also in yolk sac (YS) or AGM region at E10.0 in mouse embryos. The identification of CD61 provides a reliable marker for accessing and enriching HECs, which might greatly facilitate the understanding of HEC determination both in vivo and in vitro.

Results {#sec2}
=======

Generation of H1 hESC-*GATA2*^*w*/*eGFP*^ Cell Line {#sec2.1}
---------------------------------------------------

To target an *eGFP* into *GATA2* locus in human ESCs, we designed a pair of TALENs (transcription activator-like effector nucleases) that could target *GATA2* with high specificity and activity ([@bib6], [@bib18]) ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1D). *GATA2* TALENs along with the linearized *GATA2*/*eGFP* targeting vector were then electroporated into H1 hESCs for gene editing ([Figure 1](#fig1){ref-type="fig"}A). Further through drug selection, the correctly targeted colonies were chosen and verified by PCR with indicated primers ([Table S1](#mmc1){ref-type="supplementary-material"}). Subsequently, the drug-resistant gene was removed with Cre recombinase to obtain the final targeted H1-*GATA2*^*w*/*eGFP*^, which was further verified by both PCR ([Figure 1](#fig1){ref-type="fig"}B) and Southern bot ([Figures 1](#fig1){ref-type="fig"}C and 1D). The final H1-*GATA2*^*w*/*eGFP*^ hESCs maintained normal phenotype as do typical hESCs under undifferentiated culture conditions (data not shown). To examine the correlation between *eGFP* and *GATA2* expression, we employed OP9 co-culture for blood differentiation ([@bib44]). As shown in [Figure 1](#fig1){ref-type="fig"}E, we detected a significant cell population expressing *eGFP* at day 10 of H1-*GATA2*^*w*/*eGFP*^/OP9 co-culture ([Figure 1](#fig1){ref-type="fig"}E). The eGFP^+^ cells showed a much higher level of GATA2 expression while the eGFP^−^ cells were GATA2 negative ([Figure 1](#fig1){ref-type="fig"}F), indicating that *eGFP* expression was highly related to *GATA2* expression during differentiation. In addition, we also examined H1-*GATA2*^*w*/*eGFP*^ in a bone morphogenetic protein 4 (BMP4)-induced differentiation condition. BMP4 has been reported to induce GATA2 expression ([@bib30]), hence we examined the GATA2 and eGFP expression in H1-*GATA2*^*w*/*eGFP*^ with BMP4 treatment for 5 days. Through both real-time qPCR and western blot, we further confirmed the strict correlation between *eGFP* and *GATA2* expression in another differentiation system ([Figures 1](#fig1){ref-type="fig"}G--1I). Altogether, we demonstrated that the eGFP reporter targeted in *GATA2* locus in hESCs could be used to mark the endogenous expression of *GATA2*.

GATA2/eGFP Expression Defines HECs and HPCs in hESC Differentiation {#sec2.2}
-------------------------------------------------------------------

Since GATA2 is a pivotal factor for hematopoiesis, we then analyzed hematopoietic potential on GATA2/eGFP^+^ and GATA2/eGFP^−^ populations during blood differentiation. GATA2/eGFP^+^ cells were detected at the time when CD31^+^ cells, a previously known HEC population ([@bib31]) appeared, preceding the formation of CD43^+^ population, the HPCs identified in hESC differentiation ([@bib44]) ([Figure 2](#fig2){ref-type="fig"}A). However, the previously recognized HECs with the phenotype of CD34^+^CD31^+^CD43^−^ contained both GATA2/eGFP^+^ and GATA2/eGFP^−^ populations ([Figure 2](#fig2){ref-type="fig"}B). Upon sorting and replating onto OP9 stromal cells, only the GATA2/eGFP^+^ population could further give rise to CD34^+^CD43^+^ HPCs ([Figure 2](#fig2){ref-type="fig"}B). To further strengthen this finding, we also examined the hematopoietic potential of GATA2/eGFP-positive or -negative cells in a different co-culturing system. Upon co-culturing with another stromal cell, AGM-S3 ([@bib50]), we found again that it was the GATA2/eGFP^+^, not the GATA2/eGFP^−^ cells that could efficiently produce HPCs ([Figure S2](#mmc1){ref-type="supplementary-material"}A). In contrast, both GATA2/eGFP^+^ and GATA2/eGFP^−^ cells were able to produce monolayer endothelial cells with typical endothelial characteristics such as acetylated low-density lipoprotein (Ac-LDL) uptake and capillary structure formation ([Figure 2](#fig2){ref-type="fig"}C). In addition, both GATA2/eGFP^+^ and GATA2/eGFP^−^ cells highly express typical endothelial markers such as CD309 and CD144 ([Figure 2](#fig2){ref-type="fig"}D). These data demonstrate that at the early stage of blood differentiation, GATA2/eGFP expression marked the functional HECs and could be used to discriminate HECs from non-hemogenic endothelial cells (ECs). Furthermore, we showed that almost all CD34^+^CD43^+^ HPCs derived from HECs are also GATA2/eGFP^+^ ([Figure 2](#fig2){ref-type="fig"}E). As expected, these CD34^+^CD43^+^GATA2/eGFP^+^ HPCs were able to form different types of colony-forming unit (CFU) ([Figures 2](#fig2){ref-type="fig"}F, [S2](#mmc1){ref-type="supplementary-material"}B, and S2C). Conversely, cell populations sorted by GATA2/eGFP^+^ from OP9 co-culture exhibited HPC potential in forming different CFUs ([Figure 2](#fig2){ref-type="fig"}G). Moreover, we showed that the CFU-erythrocyte derived from GATA2/eGFP^+^ HECs and HPCs express both embryonic and adult globins, such as HBE, HBG1, and HBB ([Figures 2](#fig2){ref-type="fig"}H and 2I). This observation suggests that GATA2/eGFP^+^ HECs could give rise to HPCs representing both primitive and definitive hematopoietic systems. Taking these data together, we demonstrated that GATA2/eGFP expression labels both HECs and HPCs during blood differentiation of hPSCs.

Molecular Signature of GATA2/eGFP^+^ HECs {#sec2.3}
-----------------------------------------

We then analyzed the whole-genome transcriptome on GATA2/eGFP^+^ HECs and GATA2/eGFP^−^ ECs during hESC blood differentiation. GATA2/eGFP^+^ HECs and GATA2/eGFP^−^ ECs labeled by CD34^+^CD31^+^CD43^−^ were sorted at day 8 of OP9 co-culture and analyzed by RNA sequencing (RNA-seq). Consistent with the phenotype described above, the biological functions of genes upregulated in GATA2/eGFP^+^ HECs are more related to hematopoiesis ([Figure 3](#fig3){ref-type="fig"}A). In contrast, genes upregulated in GATA2/eGFP^−^ ECs are enriched in endothelium development and angiogenesis ([Figure 3](#fig3){ref-type="fig"}A). The critical genes known for normal function of HSC or HSC niche such as ALDH1A1, GFI1, and MYB were enriched in the eGFP^+^ cells ([@bib17]) ([Figure 3](#fig3){ref-type="fig"}C), whereas vital endothelium genes such as SOX17 and NT5E (CD73) were downregulated in the eGFP^+^ cells ([Figure 3](#fig3){ref-type="fig"}B) ([@bib9], [@bib31]). Genes known for pan-endothelial, arterial, venous, and lymphatic endothelium were highly expressed in GATA2/eGFP^−^ ECs ([Figure 3](#fig3){ref-type="fig"}D) ([Table S3](#mmc1){ref-type="supplementary-material"}). Notably, some genes related to heart development such as TBX3 ([@bib1]) and TBX18 ([@bib5]) were also expressed by GATA2-positive cells ([Figure 3](#fig3){ref-type="fig"}A). This may be attributed to the elevated expression level of certain GATA factors, GATA6 ([@bib51]) for example, in the GATA2/eGFP^+^ population, and these GATA factors are known to be involved and important in cardiac system development. However, factors involved in cardiac development may also be regulated by GATA2 during hematopoiesis, and this needs to be evaluated in future studies.

We further identified TFs that were differentially expressed in GATA2/eGFP^+^ and GATA2/eGFP^−^ populations. The highly expressed TFs in GATA2/eGFP^+^ HECs include many well-known critical factors for EHT or HPC function, such as GFI1, RUNX1, MYB, and SPI1. We then sought to investigate whether these TFs form an inter-regulatory network. Based on previously reported protein-protein interaction or gene expression data, we generated an interaction network using the identified GATA2 positively or negatively related TFs ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Notably, 92.1% of the GATA2 negatively related TFs or 83.8% of GATA2 positively related TFs fell into the regulatory interaction network, indicating that these TFs are highly connected and inter-regulated. Such a network would be valuable for further investigations on the molecular mechanism diversifying HECs and non-hemogenic ECs during hematopoiesis.

CD61 Defines Hemogenic Potential Cells during hPSC Differentiation {#sec2.4}
------------------------------------------------------------------

Identification of reliable cell-surface markers for HECs is critical in enriching well-defined HEC populations for either investigating the mechanism of EHT or developing technologies for generation of HPCs in vitro. We then re-analyzed RNA-seq data and identified differentially expressed surface markers between GATA2/eGFP^+^ HECs and GATA2/eGFP^−^ ECs as shown in [Figure 4](#fig4){ref-type="fig"}A. The marker lists include many previously known surface markers associated with hematopoietic cells. For example, NT5E (CD73) was upregulated in the GATA2/eGFP^−^ ECs but not in the GATA2/eGFP^+^ HECs, which is consistent with previously reported data ([@bib9]). Other reported hematopoietic markers such as CD62P (SELP) ([@bib32]) and CD41 (ITGA2B) ([@bib4]) were upregulated in GATA2/eGFP^+^ HECs ([Figure 4](#fig4){ref-type="fig"}A). We then selected markers that were not extensively analyzed previously and validated them by fluorescence-activated cell sorting (FACS). As shown in [Figure 4](#fig4){ref-type="fig"}B, CD226 and CD61 were highly expressed in GATA2/eGFP^+^ HECs while CD200 preferably marked GATA2/eGFP^−^ ECs. Among these markers, we were particularly interested in CD61, a member of the integrin family. Integrins are known to be critical in the regulation of cell adhesion, survival, and migration ([@bib36]). In the mouse system, CD61 has been shown to be enriched in adult HSCs with long-term repopulating potential ([@bib40]). However, whether CD61 associates with the HECs preceding the formation of HS/PCs remains unclear. To analyze the hemogenic potential of CD61^+^ or CD61^−^ ECs, we sorted and replated them on the OP9 cells, a well-established assay for identification of HECs ([@bib9]). We firstly showed that at day 8 of blood differentiation with OP9 co-culture, CD61^+^ population is almost all GATA2/eGFP^+^, while conversely, only part of the GATA2/eGFP^+^ cells (nearly one-third) are CD61^+^ ([Figure 4](#fig4){ref-type="fig"}C), indicating that CD61 marked a subset of the GATA2/eGFP^+^ population. However, GATA2/eGFP^+^CD61^+^ ECs produced significantly more CD34^+^CD43^+^ HPCs than GATA2/eGFP^+^CD61^−^ cells upon sorting and replating onto OP9 for co-culture ([Figure 4](#fig4){ref-type="fig"}C). These data suggest that the CD61 expression marked the HEC subset in the GATA2/eGFP^+^ population. We also showed that these CD61^+^ HECs retain the potential to form a capillary structure of typical ECs and thus are bipotent ([Figure 4](#fig4){ref-type="fig"}D). Since the CD61^−^ cells could also generate a certain number of HPCs ([Figure 4](#fig4){ref-type="fig"}C), we asked whether it is possible that some of these CD61^−^ cells might transit into CD61^+^ later. Indeed, upon replating onto OP9 cells for 1 day of co-culture, some CD34^+^CD31^+^CD43^−^CD61^−^ cells transited into CD34^+^CD31^+^CD43^−^CD61^+^ and then CD34^+^CD31^+^CD43^+^CD61^+^ HPCs upon differentiation for another day ([Figure S4](#mmc1){ref-type="supplementary-material"}A). In all, these data demonstrate that CD61 is a positive marker for HECs.

Since we have demonstrated the critical role of CD61 in defining HECs using a hESC *GATA2*^*w*/*eGFP*^ reporter, we then examined whether it marks HECs in other wild-type (WT) hPSCs. We thus analyzed the blood differentiation of WT hESCs and human induced pluripotent stem cells (hiPSCs), such as H1, H9, and UH1, by OP9 co-culture. We showed that the previous known HEC population defined by CD34^+^CD31^+^CD43^−^ at day 8 of OP9 co-culture contained both CD61^+^ and CD61^−^ populations. CD61^+^ cells from H1, H9, or UH1 gave rise to a significant number of CD34^+^CD43^+^ HPCs, while CD61^−^ cells generated very few CD34^+^CD43^+^ HPCs ([Figures 4](#fig4){ref-type="fig"}F and 4G). These data demonstrated that CD61 defines a subset population with hemogenic potential in previously identified CD34^+^CD31^+^CD43^−^ endothelium during hPSC blood differentiation. Again, CD61-labeled HECs from WT H1 hESCs are bipotent and can produce typical capillary structure ([Figure 4](#fig4){ref-type="fig"}D).

We went on to analyze CD61 expression in CD34^+^CD43^+^ HPCs at a later stage during blood differentiation of hPSCs. For the hESC line *GATA2*^*w*/*eGFP*^, we showed that almost all CD34^+^CD43^+^ HPCs generated by OP9 co-culture were double positive for GATA2/eGFP and CD61 ([Figure 4](#fig4){ref-type="fig"}H). Similarly, for WT hPSC lines H1, H9, and UH1, almost all CD34^+^CD43^+^ HPCs were CD61^+^ ([Figure 4](#fig4){ref-type="fig"}I), indicating that CD61 also served as a marker in defining HPCs. Indeed, we showed that the CD61^+^ cell population generated a significant number of CFUs while CD61^−^ cells failed to produce CFUs ([Figure 4](#fig4){ref-type="fig"}J). Taking these data together, we demonstrated that CD61 marked both HECs at an early stage and HPCs at a late stage of hPSC differentiation.

CD61 Defines Functional HECs in Mouse Embryo {#sec2.5}
--------------------------------------------

We then sought to examine whether CD61 defines HECs in vivo in mouse embryo. We firstly examined CD61 expression in a cell population with the EC phenotype defined as CD31^+^CD41^−^CD45^−^Ter119^−^ from YS and AGM regions at E10.0 (31--34 somite pairs) in mouse embryos. We found that this previously recognized EC population could be fractionated into CD61^high^, CD61^low^, and CD61^−^ subpopulations. The ECs with different levels of CD61 expression were then sorted and replated onto the OP9 stromal cells for further characterization of hemogenic potential ([Figure 5](#fig5){ref-type="fig"}A). Upon OP9 co-culture for 3--4 days, only the CD61^low^ population, regardless of whether from YS or AGM region, could efficiently produce typical hemogenic colonies (up to 6.6 ± 2.4 per embryo equivalent; [Figures 5](#fig5){ref-type="fig"}B and 5C). Upon further co-culture (8--9 days), the CD61^low^ fraction, although not other populations, showed robust cell expansion and generation of CD45^+^ hematopoietic cells ([Figures 5](#fig5){ref-type="fig"}B and 5C). These data demonstrate that CD61^low^ marks the subset of HECs in CD31^+^CD41^−^CD45^−^Ter119^−^ ECs in mouse early embryo. We further showed that CD61^low^ HECs from mouse embryo are bipotent and can produce typical vascular structure ([Figures 5](#fig5){ref-type="fig"}D and 5E). In all, we demonstrate that the CD61^low^ cells mark a small subset of functional HECs with bipotency in mouse embryo, and thus could be used to efficiently enrich and access functional HECs (up to a dozen-fold) in vivo for further study.

Discussion {#sec3}
==========

Hematopoiesis is a highly regulated process controlled by the coordination of TFs and diverse signaling pathways. Knowledge of the mechanisms that drive HSC development is critical for generation of functional HSCs in vitro using hPSC differentiation. To date, significant progress has been made in understanding the regulation of HSC development, as well as identification of cell-surface markers defining hematopoietic cells at different developmental stages and regions in animal models ([@bib9], [@bib22], [@bib47]). However, information on human hematopoiesis remains quite limited due to the inaccessibility of human materials. Hematopoietic differentiation of hESCs in vitro provides a valuable model for understanding human hematopoiesis. It has been known that the in vitro hematopoietic differentiation of hESCs follows the basic principle of the in vivo embryonic hematopoiesis in mouse ([@bib7]). For example, EHT has been observed during differentiation of hESCs for the generation of HPCs ([@bib33]). Our previous work also showed that the role of GATA2, a critical factor for mouse hematopoiesis, is conserved in a hESC model, as GATA2^−/−^ hESCs exhibited a significant defect in EHT and then HPC generation ([@bib18]). In the current study, we extended our previous work to generate and analyze the blood differentiation of a hESC *GATA2*^*w*/*eGFP*^ reporter cell line in vitro. We show that both HECs capable of producing HPCs and the generated HPCs are almost exclusively GATA2/eGFP^+^ cells. These data further highlight the critical role of GATA2 in the regulation of hematopoiesis. It is worth noting that a recent report showed that some HPCs in mice are independent of GATA2, although the HSCs were proved to be exclusively GATA2 expressing ([@bib21]). Our previous work also showed that GATA2^−/−^ hPSC-derived HPCs can produce a certain number of CFUs in vitro ([@bib18]). More detailed analysis of GATA2^+^ HSCs and GATA2^−^ HPCs is needed in future research to enable full understanding of the role of GATA2 during hematopoiesis.

Nevertheless, given the advantage of GATA2/eGFP as a reporter, we were able to discriminate HECs from non-hemogenic ECs in hESC hematopoietic differentiation. To investigate the molecular determinants for HE, we analyzed and compared the transcriptome of GATA2/eGFP^+^ HECs and GATA2/eGFP^−^ ECs derived from hESCs. A panel of TFs that are positive and negative for HECs or ECs were identified in a human model ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Many important TFs for hematopoiesis are relatively conserved between human and mouse. For example, the well-known TFs identified in mouse hematopoietic development, such as GFl1, RUNX1, MYB, and SPI1, are more highly expressed in GATA2/eGFP^+^ HECs than in GATA2/eGFP^−^ ECs ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Future work might need to investigate in detail the individual role of each previously unidentified TF in hematopoiesis using both human and mouse models.

Reliable cell-surface markers in defining hematopoietic cells with different potential are valuable in assessing well-defined populations for further investigation. Cell-surface markers are of particular significance for hPSC differentiation, as the in vitro system lacks anatomical and morphological information. To date, a few surface markers have been identified in defining blood cells at different stages of hESC/iPSC differentiation ([@bib9], [@bib44]). For example, CD43 has been identified as a marker for hPSC-derived HPCs with the potential to form CFUs, thus providing an easy way to isolate HPCs in vitro ([@bib44]). However, defining functional HECs has been complex and challenging due to the limitation of reliable surface markers. Our finding that the HECs are almost exclusively GATA2/eGFP^+^ allows us to identify reliable surface markers for functional HECs. Indeed, we identified a panel of cell-surface markers that differentially expressed between GATA2/eGFP^+^ HECs and GATA2/eGFP^−^ ECs. The lists include some previously identified hematopoietic markers such as CD62P and CD41, and many other unidentified ones. Among them, CD61 is of particular significance as it almost exclusively marked the small portion of HECs capable of producing HPCs in hPSC differentiation. Interestingly, almost all HPCs generated from hPSC-derived HECs are also CD61^+^. In addition, the CFU-Mix (also referred as GEMM) potential cells were restricted in the CD61^low^ cells in YS of E10 mouse embryo ([Figure S5](#mmc1){ref-type="supplementary-material"}A), indicating that CD61^low^ also labels HPCs in mouse early embryo. In another report, [@bib4] also showed that the HSCs with transplantation potential are restricted in the CD61^low^ fraction in E11 AGM and the E11 placenta, while at a later stage, as in the E12 YS and E14 fetal liver, transplantable HSCs were found in both CD61^−^ and CD61^low^ fractions, indicating that CD61 marks HSCs at the specific stage of mouse embryo.

Another integrin, CD41, was also increased in GATA2/GFP^+^ HECs. CD41 has been known as a marker to identify HPCs from mouse embryo ([@bib15]). However, mouse HECs were defined as CD41^−^ (CD31^+^CD41^−^CD45^−^Ter119^−^). Interestingly, CD61 is usually co-expressed with CD41 in many different cell types. However, our findings show that at an early stage of hematopoiesis both in vitro and in vivo, CD61 is expressed independently of CD41 in HECs. Indeed, hematopoietic cells isolated from E8 or E10 mouse embryo exhibited significant differential expression of CD61 and CD41 ([Figures S5](#mmc1){ref-type="supplementary-material"}B and S5C). Similarly, the expressions of CD41 and CD61 are not consistent in hematopoietic cells differentiated from hPSCs in vitro ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C). These data indicate that CD61 or CD41 might act independently in certain cell types or stages of hematopoiesis, but their exact roles and timing need to be investigated further. Nonetheless, our finding that CD61 is conservative in defining HECs both in vitro for hPSC differentiation and in vivo for mouse embryo provides valuable information on how to define and access the bipotent HECs. It is noteworthy that the percentage of HECs labeled by CD61 from either YS or AGM is very low, varying between 2% and 10% of previously recognized ECs ([Figure 5](#fig5){ref-type="fig"}A). Therefore, the identification of CD61 would allow dozen-fold enrichment for HECs and would greatly facilitate future research in understanding the mechanisms of HE determination and HSC generation both in vitro and in vivo.

Experimental Procedures {#sec4}
=======================

All experiments were carried out in accordance with the guidelines of the Human Subject Research Ethics Committee at Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), and all experimental protocols were approved by the committee. Formal informed consent was obtained from all subjects.

All animal experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals instructed by the Institutional Animal Care and Use Committee of Guangzhou Institutes of Biomedicine and Health (IACUC-GIBH) and all protocols were approved by the committee.

TALEN Targeting {#sec4.1}
---------------

The binding and cutting sites of GATA2 knockin TALENs are illustrated in [Figure S1](#mmc1){ref-type="supplementary-material"}, and the TALENs were designed as previously described ([@bib18]). For donor construction, left and right homology arms were cloned from genomic DNA of H1 cell line about 1 kb upstream and downstream of the stop code, respectively. A FLAG-2A-eGFP-loxP-PGK-puromycin-loxP cassette was further inserted into the homology arms in the vector pUC57. For targeting, constructed vector was initially linearized by *Eco*RI, then 1 μg of the linearized vector was electroporated into 1 × 10^6^ H1 cells with 2.5 μg of each TALEN plasmid. After the transfection, cells were seeded on Matrigel-coated 6-well plates in the presence of 10 μM Y-27632 (Sigma). Puromycin (0.5 μg/mL, Sigma) was added to the medium to select positive clones 2 or 3 days later. Drug-resistant clones were picked out and genomic DNA of these clones was used for PCR verification of successful targeting. After the verification, the targeted clones were expanded and further transfected with 400 ng of Cre recombinase for every 1 × 10^6^ cells to remove the *loxP* flanked PGK-puromycin cassette, followed by seeding in a single-cell state in the presence of Y-27632. When the clones grew up, they were picked for further verifications by genomic PCR and Southern blot.

The GFP reporter assay was performed as previously reported ([@bib18]). In brief, the GFP reporter was inserted with the WT or mutant sequence of the TALENs binding and cutting sites. The reporter was then electroporated into the 293T cells with the TALENs for test. After 48 hr, the cells were digested and examined for GFP fluorescence by FACS.

PCR and Southern Blot Verification {#sec4.2}
----------------------------------

PCR reactions were performed with KOD-Plus enzyme (Toyobo) according to the manufacturer\'s instructions. For each reaction, 50--100 ng of genomic DNA templates were used. PCR primers P1 and P2 (shown in [Figure 1](#fig1){ref-type="fig"}A) were designed to amplify 2.50-kb or 1.10-kb products. The 2.50-kb product was obtained from cell line with the *loxP* flanked PGK-puromycin cassette. After removal of the cassette, the 1.10-kb product was produced as illustrated in [Figure 1](#fig1){ref-type="fig"}B. For Southern blot, the reactions were carried out according to the manuals of DIG High Prime DNA Labeling and Detection Starter Kit II (Roche). Specifically, genomic DNA was digested by *Bgl*II endonuclease, and probes about 1 kb in length were synthesized by PCR reaction. The eGFP probe (probe 1) was used to verify the integration of a single copy of eGFP sequence in the genome, and the 3′ external probe (probe 2) was used to identify the insertion in the TALEN cutting site as designed. All primers are listed in [Table S1](#mmc1){ref-type="supplementary-material"}.

hPSC Culture and Differentiation in Co-culture {#sec4.3}
----------------------------------------------

The procedures of hESC (H1 and H9) and hiPSC (UH1) culture, and OP9-based hematopoietic differentiation were carried out as described previously ([@bib18]). In particular, gene targeting was performed at passage 38 of the H1 ESC line. In addition, CD34^+^CD31^+^CD43^−^ HECs at day 8 of hESC/OP9 co-culture and CD34^+^CD43^+^ HPCs at day 10 of hESCs/OP9 co-culture were sorted for further analysis. Furthermore, for assessment of hemogenic potential of HECs or HE subpopulation, cells sorted at day 8 of differentiation were replated onto OP9 or AGM-S3 stromal cells for 1 or 2 further days of co-culture before analysis.

FACS Analysis and Cell Sorting {#sec4.4}
------------------------------

The detailed procedure is presented in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

CFU Assay {#sec4.5}
---------

CFU assay of hESC-derived HPCs was conducted following the manufacturer\'s protocol H4435 (STEMCELL). For CFU assay of mouse scored cells, cells were plated in 0.9% methylcellulose-based medium supplemented with 15% fetal bovine serum, 2 mM glutamine, 100 U/mL penicillin-streptomycin, 5% protein-free hybridoma medium II, 200 mg/mL iron-saturated holo-transferrin, 1% BSA, 0.45 mM monothioglycerol, 100 ng/mL recombinant murine stem cell factor (PeproTech), 10 ng/mL recombinant murine interleukin-3, 10 ng/mL recombinant human interleukin-6, and 3 U/mL human erythropoietin. Colonies were scored based on the morphological criteria.

Real-Time qPCR {#sec4.6}
--------------

The detailed procedure is presented in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

RNA-Seq {#sec4.7}
-------

RNA-seq and subsequent data analysis were conducted as described by [@bib18]. In brief, total RNA was isolated with a Direct-zol RNA MiniPrep kit (Zymo Research) and sequencing libraries was prepared with a TruSeq RNA Sample Prep Kit (Illumina) following the manufacturer\'s protocol. The samples were run on an MiSeq system with MiSeq Reagent Kits v2 (50 cycles) (Illumina). In particular, RNA-seq data were processed essentially as described by [@bib20], reads were aligned to an index generated from the Ensembl transcriptome version 74 (hg19) using RSEM (v1.2.19), Bowtie2 (v2.2.5), and normalized with EDASeq (v2.2.0). Gene expression is expressed as "normalized tag count." A threshold of at least 20 normalized tags in any condition was used to filter lowly expressed transcripts. Differential expression was performed using DESeq2 (v1.8.1) and genes were considered significant if they had a Benjamini-Hochberg corrected p value (q value) \<0.1 and had a fold-change \> 1.5. Gene ontology was performed using goseq (v1.20.0). Other analyses were performed using glbase ([@bib19]).

Endothelial Cell Culture and Assays {#sec4.8}
-----------------------------------

Endothelial cell-related assays, including endothelial cell culture, DiI-Ac-LDL uptake, and capillary structure formation, were performed as described previously ([@bib18]). In brief, the eGFP^+^ and eGFP^−^ cells in CD34^+^CD31^+^CD43^−^ cells were sorted from day 8 of H1-*GATA2*^*w*/*eGFP*^/OP9 co-culture. Specifically, the DiI-Ac-LDL uptake assay was performed as per the manual\'s instructions. FACS-sorted CD61^high^, CD61^low^, and CD61^−^ cells in the CD31^+^CD41^−^CD45^−^Ter119^−^ fraction were cultured on an OP9 stromal cell layer to detect the endothelial cell colony formation in the presence of 100 ng/mL vascular endothelial growth factor. After 7 days, cultured cells were fixed with 4% paraformaldehyde and the forming capacity of endothelial tubules was assessed by immunostaining with anti-CD31 antibody (BD Pharmingen). Immunohistochemistry was performed as described previously ([@bib25]).

Mice and YS/AGM Cell Preparation {#sec4.9}
--------------------------------

The detailed procedure is presented in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Co-culture of YS and AGM Cell with OP9 {#sec4.10}
--------------------------------------

The detailed procedure is presented in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Western Blot {#sec4.11}
------------

The detailed procedure is presented in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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![Targeting of eGFP to the *GATA2* Locus in H1 hESCs\
(A) Scheme of the *GATA2* locus targeting strategy. Partial *GATA2* locus with *Bgl*II restriction sites is shown (upper) with the targeting vector below it. Homologous recombination aided by TALEN results in the replacement of stop codon with FLAG-2A-eGFP cassette (*GATA2*^*eGFPPuro*^). Removal of PGK-Puro cassette with Cre recombinase yields final *GATA2*^*eGFP*^ locus (lower). PCR primers flanking insertion cassette are labeled with P1 and P2. Probe 1, eGFP probe; Probe 2, 3′ external probe.\
(B) PCR analysis (with P1 and P2) of modified H1 hESCs. A 0.3-kb fragment represents the WT *GATA2* allele. The 3.40-kb and 1.1-kb fragments represent the insertion cassette before and after PGK-Puro cassette, respectively.\
(C and D) Southern blot analysis of the *GATA2*^*eGFP*^ H1 hESCs with probes 1 and 2. The heterozygous cell line displays both 4.10-kb and 5.12-kb fragments corresponding to *GATA2* WT and modified allele.\
(E) Flow gating strategy of eGFP^+^ and eGFP^−^ cells from the TRA-1-85^+^ fraction at day 10 of H1-*GATA2*^*w*/*eGFP*^/OP9 co-culture.\
(F) Real-time qPCR analysis of GATA2 expression in the sorted cells as in (E). Error bars represent mean + SEM of the mean of samples from three independent experiments, in this and subsequent figures, unless otherwise indicated.\
(G--I) Gating strategy of eGFP^+^ and eGFP^−^ cells from BMP4 (50 ng/mL) disposed H1-*GATA2*^*w*/*eGFP*^ cells at day 5 (G). Real-time qPCR (H) and western blot (I) (by FLAG antibody) examination of GATA2 expression in each population.](gr1){#fig1}

![eGFP Expression Marks the HECs and HPCs\
(A) FACS analysis of eGFP, CD34, CD31, and CD43 during the H1-*GATA2*^*w*/*eGFP*^/OP9 co-culture at indicated time points.\
(B) Left and middle: isolation of eGFP^+^ and eGFP^−^ cells in CD34^+^CD31^+^CD43^−^ fraction from day 8 of H1-*GATA2*^*w*/*eGFP*^/OP9 co-culture; right: FACS analysis of CD34^+^CD43^+^ HPC percentage in CD34^+^ cells. Sorted cells from the middle were co-cultured on OP9 for 2 days before colony-forming assay. Error bars represent mean + SEM of the mean of samples from four independent experiments. Asterisks indicate statistical significance determined by t test: ^∗∗∗^p \< 0.001.\
(C) Endothelial potential of eGFP^+^ and eGFP^−^ cells from CD34^+^CD31^+^CD43^−^ fraction. Phase contrast, DiI-Ac-LDL uptake, and capillary structure are shown from left to right. Scale bars represent 100 μm in this and subsequent figures unless otherwise indicated.\
(D) FACS analysis of CD309 and CD144 expression on the eGFP^+^ and eGFP^−^ cells in CD34^+^CD31^+^CD43^−^ fraction.\
(E--G) FACS analysis of eGFP expression in CD34^+^CD43^+^ cell fraction at day 10 of H1-*GATA2*^*w*/*eGFP*^/OP9 co-culture (E). CFU assay of sorted CD34^+^CD43^+^, CD34^+^CD43^−^ cells (F) and eGFP^+^, eGFP^−^ cells (G) at day 10 of H1-*GATA2*^*w*/*eGFP*^/OP9 co-culture. E, erythrocyte; G, granulocyte; M, macrophage; GM, G and M; Mix, E, G, and M.\
(H) Phase contrast, cytospin, and FACS analysis of CFU-E.\
(I) Left: real-time qPCR analysis of HBB, HBE, and HBG1 expression in CFU-E. Right: FACS analysis of HBB expression in CFU-E.](gr2){#fig2}

![Global Gene Expression Analysis of eGFP^+^ and eGFP^−^ Cells in CD34^+^CD31^+^CD43^−^ Fraction by RNA-Seq\
(A) Left: MA plot for eGFP^+^ (n = 2) and eGFP^−^ (n = 2) cells in CD34^+^CD31^+^CD43^−^ cells from day 8 of H1-*GATA2*^*w*/*eGFP*^/OP9 co-culture. The green and red dots represent 708 and 427 upregulated genes in the eGFP^−^ and eGFP^+^ cells, respectively (p \< 0.05). Right: gene ontology analysis of these upregulated genes.\
(B) Top 50 genes downregulated and upregulated in the GFP^+^ cells compared with GFP^−^ cells (p \< 0.05). Genes in red have been reported to regulate the EHT process.\
(C) Fold change of selected genes (associated with the HS/PC, the HSC niche, and myeloid, lymphoid, and erythroid cells) in eGFP^+^ cells compared with eGFP^−^ cells. ^∗^p \< 0.05.\
(D) Fold change of selected genes associated with pan-endothelial, arterial, venous, and lymphatic cells in eGFP^−^ cells compared with eGFP^+^ cells (q \< 0.1). Error bars represent mean + SEM of the mean of samples from two independent experiments from the RNA-seq data. ^∗^p \< 0.05.](gr3){#fig3}

![CD61 Expression Marks the HECs and HPCs in hPSC Differentiation\
(A) Heatmaps of top differentially expressed cell-surface markers in the eGFP^−^ and eGFP^+^ cells in CD34^+^CD31^+^CD43^−^ fraction from day 8 of H1-*GATA2*^*w*/*eGFP*^/OP9 co-culture. NT5E in red has been reported to be involved in EHT.\
(B) Expression pattern of GATA2/eGFP and selected markers (CD73, CD200, CD226, and CD61), in CD34^+^CD31^+^CD43^−^ cells at day 8 of hESCs/OP9 co-culture.\
(C) CD34^+^CD43^+^ percentage of three sorted cell subpopulations after further 2-day co-culture with OP9. Flow sorting was performed at day 8 of H1-*GATA2*^*w*/*eGFP*^/OP9 co-culture. Asterisks indicate statistical significance determined by t test: ^∗^p \< 0.05.\
(D) Endothelial potential of eGFP^+^ and eGFP^−^ cells in CD34^+^CD31^+^CD43^−^ fraction derived from H1-*GATA2*^*w*/*eGFP*^ and H1/OP9 co-culture. Phase contrast, DiI-Ac-LDL uptake, and capillary structure are shown from left to right.\
(E) Real-time qPCR validation of CD61 expression in indicated subpopulations isolated from CD34^+^CD31^+^CD43^−^ fraction at day 8 of hESCs/OP9 co-culture.\
(F) Gating strategy of CD61^+^ and CD61^−^ cell sorting from CD34^+^CD31^+^CD43^−^ fraction at day 8 of unmodified hESCs/OP9 co-culture.\
(G--I) FACS analysis (G) of CD34^+^CD43^+^ HPC generation (% of CD34^+^ cells) by H1, H9, and UH1. Cells were sorted as shown above and replated on OP9 for a further 2-day co-culture. Asterisks indicate statistical significance determined by t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01. FACS analysis of CD61 and eGFP expression in CD34^+^CD43^+^ HPC at day 10 of co-culture of OP9 with H1-*GATA2*^*w*/*eGFP*^ (H) and H1, H9, and UH1 (I).\
(J) CFU assay of sorted CD34^+^CD61^+^ and CD34^+^CD61^−^ cells at day 10 of H1, H9, and UH1/OP9 co-culture, respectively.](gr4){#fig4}

![CD61 Labels the HECs in Mouse Embryo\
(A) From left to right: picture of YS and AGM at E10 of mouse embryo, FACS analysis of CD61 expression in CD31^+^CD41^−^CD45^−^Ter119^−^ cells, and picture of typical hemogenic colony formed after co-culture with OP9 stromal cells (original magnification is 5×).\
(B and C) From left to right: hemogenic colony formation, CD45^+^ cell generation, and cell expansion in the co-culture of OP9 with the CD61^high^, CD61^low^, and CD61^−^ cells in CD31^+^CD41^−^CD45^−^Ter119^−^ fraction isolated from E10 in YS (B) and AGM (C) regions, respectively. ee, embryo equivalent. Error bars represent mean + SEM of the mean of samples from five independent experiments. Asterisks indicate statistical significance determined by t test: ^∗∗^p \< 0.01.\
(D) Phase contrast of tube formation of the CD61^high^, CD61^low^, and CD61^−^ cells in CD31^+^CD41^−^CD45^−^Ter119^−^ fraction. The tubes were stained by anti-CD31 antibody via immunohistochemistry and are indicated by the red arrows.\
(E) Statistical analysis of tube formation per 100 cells. Error bars represent mean + SEM of the mean of samples from four independent experiments.](gr5){#fig5}
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